Brendan Jacka

ORCID: 0000-0002-5910-853X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatitis C virus research
  • HIV, Drug Use, Sexual Risk
  • Hepatitis B Virus Studies
  • Opioid Use Disorder Treatment
  • HIV/AIDS Research and Interventions
  • Substance Abuse Treatment and Outcomes
  • Liver Disease Diagnosis and Treatment
  • Prenatal Substance Exposure Effects
  • Suicide and Self-Harm Studies
  • Hormonal and reproductive studies
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • COVID-19 and Mental Health
  • Primary Care and Health Outcomes
  • Emergency and Acute Care Studies
  • Poisoning and overdose treatments
  • Intensive Care Unit Cognitive Disorders
  • Long-Term Effects of COVID-19
  • Migration, Health and Trauma
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Interpreting and Communication in Healthcare
  • Behavioral Health and Interventions
  • Doping in Sports
  • Alcohol Consumption and Health Effects
  • Posttraumatic Stress Disorder Research

UNSW Sydney
2013-2025

John Brown University
2020-2024

Brown University
2020-2023

BDH Bundesverband Rehabilitation
2022

CSD Engineers (Switzerland)
2022

Centre Hospitalier de l’Université de Montréal
2019-2020

Providence College
2020

Rhode Island Hospital
2020

Université de Montréal
2019

Institut National de Santé Publique
2019

Abstract This study investigates the humoral and cellular immune responses health-related quality of life measures in individuals with mild to moderate long COVID (LC) compared age gender matched recovered COVID-19 controls (MC) over 24 months. LC participants show elevated nucleocapsid IgG levels at 3 months, higher neutralizing capacity up 8 months post-infection. Increased spike-specific nucleocapsid-specific CD4 + T cells, PD-1, TIM-3 expression on CD8 cells were observed but these...

10.1038/s41467-024-47720-8 article EN cc-by Nature Communications 2024-04-17

Objectives. To determine the number of people who inject drugs (PWID) in Canada and annual coverage opioid agonist treatment (OAT) needle-and-syringe provision for PWID. Methods. We estimated PWID 11 13 Canadian provinces territories 2011 by using indirect multiplier methods based on provincial territorial methadone recipient totals proportion surveyed receiving methadone. modeled increases to 2016 Quebec British Columbia longitudinal data. calculated (World Health Organization [WHO]...

10.2105/ajph.2019.305379 article EN American Journal of Public Health 2019-11-14

<h3>Importance</h3> Fatal and nonfatal opioid overdoses are at record levels, emergency department (ED) visits may be an opportune time to intervene. Peer-led models of care increasingly common; however, little is known about their effectiveness. <h3>Objective</h3> To evaluate the effect a peer-led behavioral intervention compared with standard delivered in ED on engagement substance use disorder (SUD) treatment within 30 days after encounter. <h3>Design, Setting, Participants</h3> This...

10.1001/jamanetworkopen.2022.25582 article EN cc-by-nc-nd JAMA Network Open 2022-08-09

Little is known about factors associated with hepatitis C virus (HCV) transmission among people who inject drugs (PWID). Phylogenetic clustering and were evaluated PWID in Vancouver, Canada. Data derived from the Vancouver Injection Drug Users Study. Participants HCV antibody-positive at enrolment those antibody seroconversion during follow-up (1996 to 2012) tested for RNA sequenced (Core-E2 region). trees inferred using maximum likelihood analysis clusters identified ClusterPicker (90%...

10.1002/hep.27310 article EN Hepatology 2014-07-15

Sequencing is important for understanding the molecular epidemiology and viral evolution of hepatitis C virus (HCV) infection. To date, there little standardisation among sequencing protocols, in-part due to high genetic diversity that observed within HCV. This study aimed develop a novel, practical protocol covered both conserved variable regions genome assess influence each subregion, sequence concatenation unrelated reference sequences on phylogenetic clustering analysis. The Core...

10.1371/journal.pone.0131437 article EN cc-by PLoS ONE 2015-07-20

Abstract Background Individuals with Long COVID experience substantial burden of illness many months after initial infection. Few studies have comprehensively and longitudinally assessed health outcomes for people following mild/moderate We applied the Wilson-Cleary model health-related quality life (HRQOL) to describe impact on multiple dimensions up 24 COVID-19 Methods Participants within ADAPT post-COVID study (n=172, 86% infection) completed structured patient-reported outcome measures...

10.1093/ofid/ofaf142 article EN cc-by-nc-nd Open Forum Infectious Diseases 2025-03-27

Abstract Introduction and Aims Emerging research suggests that the sub‐population of anabolic–androgenic steroid (AAS) users who experience physical appearance concerns may suffer greater psychological dysfunction than other sub‐populations, including with athletic or occupational concerns. Thus, among current AAS users, we sought to determine whether, what extent, social physique anxiety—an established measure concern—was associated dysfunction. Design Methods Interviews were conducted a...

10.1111/dar.12688 article EN Drug and Alcohol Review 2018-02-27

ABSTRACT The storage of biological samples may affect detection viral nucleic acid, yet the stability acid at standard laboratory temperatures (−70°C and −20°C) has not been comprehensively assessed. Deterioration RNA DNA during viruses, thus leading to an increased likelihood false-negative results on diagnostic testing. loads 99 hepatitis C virus (HCV), 41 HIV, 101 B (HBV) patient were measured before after −20°C −70°C for up 9.1 years using Versant branched assays, Cobas Monitor and/or...

10.1128/jcm.02447-10 article EN Journal of Clinical Microbiology 2011-07-14

Opioid agonist treatment is considered important in preventing acquisition of hepatitis C virus (HCV) among people who inject drugs; however, the role dosage opioid unclear. We investigated joint association prescribed and patient-perceived adequacy with risk HCV infection drugs.We followed prospectively drugs at acquiring (who were RNA negative HCV-antibody or positive) Montréal, Canada (2004-2017). At 6-month, then 3-month intervals, participants tested for antibodies RNA, completed an...

10.1503/cmaj.181506 article EN cc-by-nc-nd Canadian Medical Association Journal 2019-04-28

Improved surveillance methods are needed to better understand the current hepatitis C virus (HCV) disease burden and monitor impact of prevention treatment interventions on HCV transmission dynamics. Sanger sequencing (HCV NS5B, HVR1 Core-E1-HVR1) phylogenetics were applied samples from individuals diagnosed with in British Columbia, Canada 2011. This included two or three sequential collected <1 year apart. Patristic distances between used set cutoffs identify recent clusters. Factors...

10.1016/j.meegid.2015.04.017 article EN cc-by-nc-nd Infection Genetics and Evolution 2015-04-26

Background Although people who inject performance- and image-enhancing drugs (PIEDs) report fewer unsafe injecting practices, stigma discrimination may negatively impact their access to help information. Engagement with health care services, compared social networks (friends, relatives, gym associates) the Internet media (steroid user forums, information sites, magazines), be important for harm minimization. Methods A cross-sectional or in-person survey of men use PIEDs in Australia...

10.1080/08897077.2019.1635954 article EN Substance Abuse 2019-09-23

Before the coronavirus disease 2019 pandemic, federal law required in-person evaluation before buprenorphine initiation. Regulatory changes during pandemic allow for initiation by audio-only or audiovisual telehealth. Little is known about treatment engagement after conducted via telehealth.A retrospective cohort study of 94 individuals who received initial through an encounter between April 2020 and February 2021 was performed. Participant demographics, substance use history, withdrawal...

10.1097/adm.0000000000001077 article EN Journal of Addiction Medicine 2022-09-14
Coming Soon ...